M. Shum

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).

P. Jänne, J. Nemunaitis, J. Christensen, 2016 .

Delayed Intracranial Vasospasm following Carotid Endarterectomy

J. Campellone, M. Shum, H. Dagher, 2005, Cerebrovascular Diseases.

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

T. Mok, E. Felip, S. Dakhil, 2021 .

Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).

J. Nemunaitis, D. Ferry, L. Gandhi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

S899 INHIBITION OF C3 WITH APL-2 CONTROLS HAEMOLYSIS AND INCREASES HAEMOGLOBIN LEVELS IN SUBJECTS WITH AUTOIMMUNE HAEMOLYTIC ANAEMIA (AIHA)

M. Gertz, E. Roman, B. Fattizzo, 2019, HemaSphere.

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA)

M. Gertz, E. Roman, Pascal Deschatelets, 2018, Blood.

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Xiwen Ma, Seung Tae Lee, M. Leiba, 2021, Blood.